Dr. Reddy’s Laboratories (RDY) to Post Quarterly Earnings on Wednesday

Dr. Reddy’s Laboratories (NYSE:RDY) will likely be releasing its Q1 26/27 results before the market opens on Wednesday, July 22nd. Analysts expect Dr. Reddy’s Laboratories to announce earnings of $0.0927 per share and revenue of $856.8460 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 26/27 earning results page for the latest details on the call scheduled for Wednesday, July 22, 2026 at 10:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a net margin of 12.90% and a return on equity of 12.34%. The business had revenue of $852.55 million during the quarter, compared to analyst estimates of $886.58 million. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $12.85 on Wednesday. The company has a 50-day moving average of $13.65 and a 200-day moving average of $13.73. The firm has a market cap of $10.72 billion, a price-to-earnings ratio of 22.15, a price-to-earnings-growth ratio of 1.95 and a beta of 0.25. The company has a current ratio of 1.80, a quick ratio of 1.34 and a debt-to-equity ratio of 0.03. Dr. Reddy’s Laboratories has a twelve month low of $12.19 and a twelve month high of $15.67.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of RDY. Russell Investments Group Ltd. raised its holdings in Dr. Reddy’s Laboratories by 803.8% during the 4th quarter. Russell Investments Group Ltd. now owns 3,091 shares of the company’s stock worth $43,000 after buying an additional 2,749 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after buying an additional 1,294 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Dr. Reddy’s Laboratories in the second quarter worth about $67,000. Public Employees Retirement System of Ohio purchased a new position in shares of Dr. Reddy’s Laboratories in the fourth quarter worth approximately $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Dr. Reddy’s Laboratories in the third quarter worth approximately $78,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on RDY. Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. The Goldman Sachs Group lowered shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, April 23rd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce”.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.